Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance

Int J Cancer. 1999 Jun 21;84(3):239-43. doi: 10.1002/(sici)1097-0215(19990621)84:3<239::aid-ijc7>3.0.co;2-s.

Abstract

In order to examine whether or not the expression of the apoptosis-related receptor Fas (CD-95/APO-1) and its ligand (FasL) has relevance for patient survival, immunohistochemistry was used to analyze the proteins of both factors in 164 non-small cell lung carcinomas. Patients with Fas-positive tumors exhibited significantly longer survival times than patients with Fas-negative carcinomas. In contrast, FasL did not significantly influence patient survival time. A multivariate analysis of clinical and biological factors indicated that lymph node status and Fas expression were significant prognostic factors. Carcinoma patients who were negative for both Fas and FasL had a significantly higher incidence of lymph node involvement than did carcinoma patients who were positive for Fas and FasL. Carcinomas that were positive for Fas and FasL demonstrated a greater sensitivity to doxorubicin in vitro.

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Non-Small-Cell Lung / chemistry*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Doxorubicin / therapeutic use
  • Fas Ligand Protein
  • Female
  • Humans
  • Immunohistochemistry
  • Lung Neoplasms / chemistry*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / mortality
  • Lymphatic Metastasis
  • Male
  • Membrane Glycoproteins / analysis*
  • Middle Aged
  • Prognosis
  • Survival Rate
  • fas Receptor / analysis*

Substances

  • FASLG protein, human
  • Fas Ligand Protein
  • Membrane Glycoproteins
  • fas Receptor
  • Doxorubicin